At OctaGenix®, we strive to make life better for everyone by providing easy access to ground-breaking medicines.
We are a privately owned British company with a global presence and headquarters in Holborn, London, and Waltham Abbey, Essex.
Unlike other generic companies, we focus on introducing new and innovative generics of high-cost Orphan Drugs, Bio-similar products, and unlicensed special medicines to the global markets. Our aim is to improve patient management and access, increase treatment options, and address health and care inequalities. To achieve this, we constantly work on developing and sourcing high-quality products and investing in Ai and Medical technologies. As we continue to grow, we are well-positioned to expand into other specialty areas.
Our Specialty
OctaGenix® specialises in the areas such as oncology, obesity, infection control, viral diseases, medical cannabis, drug delivery systems, and unlicensed specials medicines. Our motto, “Patients are in our DNA” is not just a slogan but the foundation of our company.
At OctaGenix®, we are committed to providing patients with a choice of well-being. Our business strategy aims to create value and improve access to much-needed treatments, ultimately enhancing and prolonging patients’ lives. Our mission is to become the go-to source for generic or high-cost Orphan Drugs and bio-similar products. We are dedicated to improving the health and well-being of the patients, thoughtfully identifying their needs, and finding better ways to serve them. We are excited to continue our journey by offering more valuable medicines, innovative solutions, and cost-effective treatments to the UK and global markets.
We work closely with organizations like the NHS, MHRA, and NICE to solidify our position as a true partner. Our goal is to provide life-saving medicine to more patients by offering cost-effective generics of Orphan Drugs and Biosimilars. Our integrity, knowledge, experience, and innovation capabilities set us apart in the industry and enable us to make a difference in communities. We strive to be the first choice for help when it’s needed.
A brief overview of what we do
At OctaGenix®, we strive to raise awareness about various health risks that can pose a threat to life and are preventable. Our company has been researching and developing solutions to address obesity related health issues, including cancer, diabetes, high blood pressure, heart problems, endocrine, and metabolic disorders. Our focus is not limited to obesity but extends to identifying and treating such conditions at an early stage.
We strongly believe in the adage “prevention is better than cure.”
We’re not just another ‘generic manufacturer’
At OctaGenix®, we focus on research to offer unique solutions that cater to the needs of patients and healthcare systems. We are not a typical generic manufacturing company and are passionate about exploring various fields, such as medical cannabis, food supplements, MedTech, and ground-breaking A.I. technology. Our goal remains to explore every possible avenue to combat disease to help patients and support healthcare systems through our research and innovation.
OctaGenix®, aims to ensure the durability of healthcare systems, enhance the pharmacoeconomic performance of drugs, and reduce the pressures on stretched healthcare budgets.
We achieve this by sourcing, creating, and providing affordable and only the best quality pharmaceuticals, making patients access easy to clinically effective high-cost treatments.
The healthcare industry is constantly evolving, and the use of orphan drugs and their efficacy versus costs and supply models are scrutinised and challenged by the NHS, funders, and healthcare providers.
With our approach, OctaGenix® is in a great position to work collaboratively with all the stakeholders to improve the delivery of effective pharmaceuticals at affordable costs and provide support to enhance patient care in hospitals, homes, and clinical settings. Our extensive knowledge and understanding of the complex NHS processes enable us to market our products and services more effectively in accordance with local and national health guidelines. OctaGenix® will continue sourcing only the highest quality, cost-effective generic pharmaceuticals, and Bio-similar products through our reliable and respected global partners to improve patients’ care and access while delivering efficiencies, increasing productivity, and leading to significant savings for the NHS, patients, providers, and payers.
Our top priority is the well-being of our patients.
To ensure they have access to the treatments they need, we are committed to providing high-quality pharmaceuticals to the NHS at affordable cost. Our approach is socially responsible and focused on improving the quality of life and dignity of patients. We never cut corners and work hard to achieve positive results. We collaborate closely with the NHS, local health boards, renowned clinicians, patient support groups, commissioning groups, and regulators to carefully select the safest and most appropriate products for the UK market.
At OctaGenix®, we place patients at the forefront of our business.
Our business model is designed to cater to the needs of patients.
We work in collaboration with our commercial partners, healthcare professionals, and NHS stakeholders to deliver premium healthcare services. We believe that patients should have easy, safe, and affordable access to innovative treatments. We are proud to make a real difference in the lives of our patients and support the NHS in delivering high-quality healthcare. Our team carefully listens to patients’ and clinicians’ needs to provide solutions that address the emotional impact of being denied access to new and innovative treatments.
We encourage you to contact us, whether to enquire about our products or to offer your thoughts as to how we can best serve our patients. Please do not hesitate to get in touch.
Since Brexit, the UK’s healthcare system is experiencing a severe shortage of staff. The flow of trained workforce from the EU has ceased, and many who were already working in the system have returned home.
Unfortunately, the government and NHS did not adequately plan for this transitional phase, resulting in a sharp decline in the trained medical staff.
The situation has recently worsened due to pay disputes and high job demands putting patients’ lives at risk. The issue will be ongoing since predicting future workforce needs is challenging, given the long training times for healthcare professionals. For example, it takes three years to train a nurse, ten years to train a general practitioner (GP), and approximately 15 years to train a consultant. As a result, workforce planners may not anticipate the landscape by the time these professionals join the workforce.
Our goal in MedTech is to utilise AI to improve patients’ subsequent management in the community. Our AI devices will make administering complicated injectable therapies easier, increase patient compliance, and securely share information about adverse events, pharmacovigilance, quality of life, and overall survival data with clinicians, hospital staff, pharmacies, academics, researchers, and pharmaceutical companies. Additionally, we plan to increase the availability of emergency drugs, specifically those used in cancer treatment. We are working towards forming partnerships with leading US companies to bring their quality pharmaceuticals to the UK and address unmet healthcare needs while collaborating closely with the MHRA and FDA.
At OctaGenix®, we understand that healthcare professionals require more than just a pharmaceutical product. They need dedicated business partners who can help them to navigate the challenges of working in the healthcare sector. We aim to be those partners by aligning our business functions with the rapidly changing needs of the NHS environment. Our goal is to eliminate healthcare inequalities within our communities and to make a positive impact on tomorrow. Unlike other businesses, we are committed to addressing the real challenges facing the NHS. We won’t just cover up the problems, but instead, we will collaborate with the NHS to devise pragmatic solutions.
At OctaGenix®, we are driven by our mission to serve, with the goal of shaping a better healthcare system for the future. To achieve this, we hold ourselves to the core values of honesty, integrity, and commitment. We believe in providing easily accessible healthcare to all, and we do so by being open, clear, and straightforward in our dealings with healthcare professionals. We plan to fulfil our obligations by delivering real value to the people and communities that we serve by sourcing, developing, and supplying only the highest quality, well-tolerated, and cost-effective pharmaceuticals. Ultimately, we aim to improve access to treatments and minimise costs.
A few words from our CEO – Mr. Zulfiqar Khan
My team and I come to work daily with a concurrent mission of helping everyone lead a happy and healthy life. We offer a wide range of products and services, prescription pharmaceuticals, innovative solutions, and MedTech powered by Artificial Intelligence, with the objective to improve patient access to medicine, enhance the quality of life, and eliminate healthcare inequalities.
We work closely with organisations like the NHS, MHRA, and NICE to solidify our position as a true partner. Our goal is to provide life-saving medicine to more patients by offering cost-effective generics of Orphan Drugs and Biosimilars. Our integrity, knowledge, experience, and innovation capabilities set us apart in the industry and enable us to make a difference in communities. We strive to be the first choice for help when it’s needed.
Statement from our Digital Marketing Manager – Mr. Luca Coyte
OctaGenix Pharmaceuticals Limited is a leading infrastructure, that prides itself in helping everyone to lead a productive, healthy, high-quality life. We constantly strive to offer a unique range of products and services, from prescription pharmaceuticals to innovative solutions, delivering efficiencies. Our main goals are to enhance patient access to medicine, increase the quality of life, and to abolish any inequalities.
To best serve our clients, we believe in establishing international strategic partnerships to strengthen all activities from development and commercialisation to product supply and marketing. We work on joint projects with the NHS, MHRA, and NICE, to consolidate our position as one of their true partners. We pride ourselves on being able to provide more patients with the chance of life-saving medicine, by bringing cost-effective generics and biosimilar to the market at a fraction of the cost as compared to research products. This, in turn, will provide more patients the chance to get the treatment that they deserve.
Our integrity, knowledge, experience in the industry, and capabilities to innovate, enable us to be best positioned to help communities. Unfortunately, none of us can predict what lies around the corner, and if the time should come when help is needed, we want to be your first choice. Lately, we have been extremely focused with the development of our iSMART system, however, we welcome you to contact us.
